Association Between Liver Fibrosis and Osteoporosis in Adults Aged 50 and Older: Insights from the Bushehr Elderly Health Program

Overview

Journal J Diabetes Metab Disord

Date 2025 Feb 10

PMID 39927178

Authors

Azin Soltani

Amirhossein Aghakhani

Hojat Dehghanbanadaki

Ziba Majidi

Mostafa Rezaei-Tavirani

Gita Shafiee

Afshin Ostovar

Seyed Amirhossein Mir Moeini

Fatemeh Bandarian

Bagher Larijani

Iraj Nabipour

Noushin Fahimfar

Farideh Razi

Affiliations

Soon will be listed here.

Abstract

Objectives: Both liver fibrosis and osteoporosis share inflammatory pathways, with liver fibrosis potentially contributing to decreased bone mineral density (BMD). The rising prevalence of non-alcoholic fatty liver disease (NAFLD) and associated liver fibrosis, especially in older populations, may increase the risk of osteoporosis, but evidence remains inconclusive. This study aims to investigate the relationship between liver fibrosis and osteoporosis in individuals over 50 years old.

Methods: This cross-sectional study used data from the Bushehr Elderly Health Program (BEHP), a cohort of 2,000 participants aged 50 and older, selected through multistage stratified random sampling. BMD and trabecular bone score (TBS) measurements were assessed. The Fibrosis-4 (FIB-4) index, a surrogate marker for liver fibrosis, was also calculated to examine its association with these bone health indicators. Multiple linear regression was applied to assess the relationship between FIB-4 and lumbar, hip, femoral neck BMD, and TBS scores, while logistic regression was used to evaluate osteoporosis as the dependent variable.

Results: A total of 1,959 participants with adequate data were included in our analysis. 538 participants had osteoporosis, 936 participants had osteopenia, and 485 participants had normal bone density. FIB-4 index was higher in osteoporotic groups (1.45 ± 0.90) than in osteopenic (1.26 ± 0.58, < 0.001) and normal groups (1.17 ± 0.48, < 0.001). After controlling for confounders, FIB-4 index was negatively associated with hip BMD (β=-0.0162; 95% CI: -0.0313, -0.0012 and β=-0.0221; 95% CI: -0.0340, -0.0102), femoral neck BMD (β=-0.0216; 95% CI: -0.0356, -0.0076 and β=-0.0233; 95% CI: -0.0342, 0.0124), and TBS (β=-0.0154; 95% CI: -0.0264, -0.0043 and β=-0.0244; 95% CI: -0.0338, -0.0149) in both genders and with lumbar BMD in women (β=-0.0176; 95% CI: -0.0307, -0.0045). An increase in the FIB-4 index was associated with more than a twofold rise in the risk of developing osteoporosis in women (OR = 2.123; 95% CI: 1.503, 3.000; < 0.001) and a 36% higher risk in men (OR = 1.366; 95% CI: 1.012, 1.844; = 0.042).

Conclusions: Liver fibrosis is associated with decreased bone density and attenuated bone architecture. Elevated FIB-4 index has been identified as a risk factor for osteoporosis, indicating a potential link between liver fibrosis and deteriorating bone health.

References

Gullberg B, Johnell O, Kanis J . World-wide projections for hip fracture. Osteoporos Int. 1997; 7(5):407-13. DOI: 10.1007/pl00004148. View

Zhang W, Li Y, Li S, Zhou J, Wang K, Li Z . Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients. Front Endocrinol (Lausanne). 2023; 14:1278505. PMC: 10729660. DOI: 10.3389/fendo.2023.1278505. View

Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D . Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023; 8(8):714-725. DOI: 10.1016/S2468-1253(23)00017-1. View

Kim G, Kim K, Rhee Y, Lim S . Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS One. 2017; 12(7):e0182202. PMC: 5536288. DOI: 10.1371/journal.pone.0182202. View

Anstee Q, Berentzen T, Nitze L, Jara M, Jensen A, Kjaer M . Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2024; 36:100780. PMC: 10769893. DOI: 10.1016/j.lanepe.2023.100780. View

Verdelho Machado M, Diehl A . Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology. 2016; 150(8):1769-77. PMC: 4887389. DOI: 10.1053/j.gastro.2016.02.066. View

Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S . Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 2014; 45(7):771-81. DOI: 10.1111/hepr.12408. View

. [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. Zhonghua Gan Zang Bing Za Zhi. 2018; 26(3):195-203. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.008. View

Yang Y, Kim D . An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. Int J Mol Sci. 2021; 22(5). PMC: 7961345. DOI: 10.3390/ijms22052604. View

10.

Florencio-Silva R, Sasso G, Sasso-Cerri E, Simoes M, Cerri P . Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int. 2015; 2015:421746. PMC: 4515490. DOI: 10.1155/2015/421746. View

11.

Razi F, Ostovar A, Fahimfar N, Amoli M, Fana S, Dimai H . Protocol for preliminary, multicenteric validation of "PoCOsteo device": A point of care tool for proteomic and genomic study of osteoporosis. Biol Methods Protoc. 2024; 9(1):bpae006. PMC: 10978377. DOI: 10.1093/biomethods/bpae006. View

12.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

13.

Mantovani A, Dauriz M, Gatti D, Viapiana O, Zoppini G, Lippi G . Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther. 2019; 49(4):375-388. DOI: 10.1111/apt.15087. View

14.

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

15.

Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C . Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol. 2021; 36(11):3002-3014. DOI: 10.1111/jgh.15631. View

16.

Li C, Cui Y, Zhou W, Zhang Y, Huang X, Yu F . Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2024; 2023:9957194. PMC: 11390221. DOI: 10.1155/2023/9957194. View

17.

Barchetta I, Lubrano C, Cimini F, Dule S, Passarella G, Dellanno A . Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease. Hepatol Int. 2022; 17(2):357-366. DOI: 10.1007/s12072-022-10461-1. View

18.

Azizieh F, Shehab D, Jarallah K, Mojiminiyi O, Gupta R, Raghupathy R . Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD. J Inflamm Res. 2019; 12:99-108. PMC: 6503650. DOI: 10.2147/JIR.S203590. View

19.

Cobbina E, Akhlaghi F . Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211. PMC: 5576152. DOI: 10.1080/03602532.2017.1293683. View

20.

Thrailkill K, Lumpkin Jr C, Bunn R, Kemp S, Fowlkes J . Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005; 289(5):E735-45. PMC: 2387001. DOI: 10.1152/ajpendo.00159.2005. View